CN103819478A - 阿拉格列汀中间体2-甲基-吡唑并[1,5-a]嘧啶-6-羧酸的制备方法 - Google Patents
阿拉格列汀中间体2-甲基-吡唑并[1,5-a]嘧啶-6-羧酸的制备方法 Download PDFInfo
- Publication number
- CN103819478A CN103819478A CN201410109842.0A CN201410109842A CN103819478A CN 103819478 A CN103819478 A CN 103819478A CN 201410109842 A CN201410109842 A CN 201410109842A CN 103819478 A CN103819478 A CN 103819478A
- Authority
- CN
- China
- Prior art keywords
- reaction
- methyl
- pyrimidine
- pyrazolo
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YHVGUXFUOSJCFJ-UHFFFAOYSA-N 2-methylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound N1=CC(C(O)=O)=CN2N=C(C)C=C21 YHVGUXFUOSJCFJ-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 claims abstract description 40
- FYTLHYRDGXRYEY-UHFFFAOYSA-N 5-Methyl-3-pyrazolamine Chemical compound CC=1C=C(N)NN=1 FYTLHYRDGXRYEY-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000006482 condensation reaction Methods 0.000 claims abstract description 22
- 239000007787 solid Substances 0.000 claims abstract description 19
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 239000011230 binding agent Substances 0.000 claims abstract description 9
- 238000009833 condensation Methods 0.000 claims abstract description 3
- 230000005494 condensation Effects 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 78
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 40
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 29
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 claims description 17
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 10
- 238000000967 suction filtration Methods 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000012670 alkaline solution Substances 0.000 claims description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 9
- 235000015320 potassium carbonate Nutrition 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- 235000017550 sodium carbonate Nutrition 0.000 claims description 7
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 6
- 229940043279 diisopropylamine Drugs 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 abstract description 20
- 238000001035 drying Methods 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 239000003513 alkali Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 18
- 239000012043 crude product Substances 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000010923 batch production Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- OPCJOXGBLDJWRM-UHFFFAOYSA-N 1,2-diamino-2-methylpropane Chemical compound CC(C)(N)CN OPCJOXGBLDJWRM-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 229960002050 hydrofluoric acid Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- GNVRJGIVDSQCOP-UHFFFAOYSA-N n-ethyl-n-methylethanamine Chemical compound CCN(C)CC GNVRJGIVDSQCOP-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- GDASVOXREDJRGF-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-6-carboxylic acid Chemical compound C1=C(C(=O)O)C=NC2=CC=NN21 GDASVOXREDJRGF-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410109842.0A CN103819478B (zh) | 2014-03-21 | 2014-03-21 | 阿拉格列汀中间体2-甲基-吡唑并[1,5-a]嘧啶-6-羧酸的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410109842.0A CN103819478B (zh) | 2014-03-21 | 2014-03-21 | 阿拉格列汀中间体2-甲基-吡唑并[1,5-a]嘧啶-6-羧酸的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103819478A true CN103819478A (zh) | 2014-05-28 |
CN103819478B CN103819478B (zh) | 2016-05-04 |
Family
ID=50754806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410109842.0A Active CN103819478B (zh) | 2014-03-21 | 2014-03-21 | 阿拉格列汀中间体2-甲基-吡唑并[1,5-a]嘧啶-6-羧酸的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103819478B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015152319A1 (ja) * | 2014-04-02 | 2015-10-08 | 株式会社 三和化学研究所 | 5,7-無置換-ピラゾロ[1,5-a]ピリミジン-6-カルボン酸の製造方法 |
CN105315284A (zh) * | 2014-07-23 | 2016-02-10 | 上海医药工业研究院 | 阿拉格列汀中间体的制备方法 |
CN110003218A (zh) * | 2019-03-26 | 2019-07-12 | 杭州瀚康生物医药科技有限公司 | 阿拉格列汀中间体的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101171256A (zh) * | 2005-03-14 | 2008-04-30 | 葛兰素集团有限公司 | 具有组胺h3受体亲和性的稠合噻唑衍生物 |
CN101535313A (zh) * | 2006-10-30 | 2009-09-16 | 诺瓦提斯公司 | 作为蛋白激酶调节剂的3-氨基羰基取代的稠合的吡唑衍生物 |
WO2014034626A1 (ja) * | 2012-08-28 | 2014-03-06 | 株式会社 三和化学研究所 | N-[2-({2-[(2S)-2-シアノピロリジン-1-イル]-2-オキソエチル}アミノ)-2-メチルプロピル]-2-メチルピラゾロ[1,5-a]ピリミジン-6-カルボキサミドの結晶 |
WO2014034871A1 (ja) * | 2012-08-30 | 2014-03-06 | 株式会社 三和化学研究所 | 脂質異常症の予防又は治療薬 |
CN103626775A (zh) * | 2013-12-02 | 2014-03-12 | 南京华威医药科技开发有限公司 | 具有二嗪结构的dpp-4抑制剂 |
-
2014
- 2014-03-21 CN CN201410109842.0A patent/CN103819478B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101171256A (zh) * | 2005-03-14 | 2008-04-30 | 葛兰素集团有限公司 | 具有组胺h3受体亲和性的稠合噻唑衍生物 |
CN101535313A (zh) * | 2006-10-30 | 2009-09-16 | 诺瓦提斯公司 | 作为蛋白激酶调节剂的3-氨基羰基取代的稠合的吡唑衍生物 |
WO2014034626A1 (ja) * | 2012-08-28 | 2014-03-06 | 株式会社 三和化学研究所 | N-[2-({2-[(2S)-2-シアノピロリジン-1-イル]-2-オキソエチル}アミノ)-2-メチルプロピル]-2-メチルピラゾロ[1,5-a]ピリミジン-6-カルボキサミドの結晶 |
WO2014034871A1 (ja) * | 2012-08-30 | 2014-03-06 | 株式会社 三和化学研究所 | 脂質異常症の予防又は治療薬 |
CN103626775A (zh) * | 2013-12-02 | 2014-03-12 | 南京华威医药科技开发有限公司 | 具有二嗪结构的dpp-4抑制剂 |
Non-Patent Citations (1)
Title |
---|
HOLZER, W,等: "N-1 SUBSTITUTED ETHYL 4-PYRAZOLECARBOXYLATES - SYNTHESIS AND SPECTROSCOPIC INVESTIGATIONS", 《JOURNAL OF HETEROCYCLIC CHEMISTRY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015152319A1 (ja) * | 2014-04-02 | 2015-10-08 | 株式会社 三和化学研究所 | 5,7-無置換-ピラゾロ[1,5-a]ピリミジン-6-カルボン酸の製造方法 |
CN105315284A (zh) * | 2014-07-23 | 2016-02-10 | 上海医药工业研究院 | 阿拉格列汀中间体的制备方法 |
CN110003218A (zh) * | 2019-03-26 | 2019-07-12 | 杭州瀚康生物医药科技有限公司 | 阿拉格列汀中间体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103819478B (zh) | 2016-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101298463B (zh) | 一种克林霉素磷酸酯的制备方法 | |
CN100355732C (zh) | 2-氯-5-氟-烟酸酯及酸的制备方法 | |
CN102603607B (zh) | (r)-奥拉西坦的制备方法 | |
CN103724261B (zh) | 一种硫酸羟基氯喹啉的工业化制备方法 | |
CN101812095B (zh) | 三氯蔗糖的制备方法 | |
CN103819478B (zh) | 阿拉格列汀中间体2-甲基-吡唑并[1,5-a]嘧啶-6-羧酸的制备方法 | |
CN104387427A (zh) | 一种三氯蔗糖的生产方法 | |
CN102321043A (zh) | 一种4-甲基-5-乙氧基-噁唑的制备方法 | |
CN104059023B (zh) | 维生素b1关键中间体2-甲基-4-氨基-5-氨基甲基嘧啶的环保制备方法 | |
CN103435642B (zh) | 一种磷酸三辛酯的生产方法 | |
CN103553903A (zh) | 从加工米糠油的下脚料中提取≥98%天然阿魏酸的新工艺 | |
CN103554207A (zh) | 一种羊毛脂胆固醇生产工艺 | |
CN104961710A (zh) | 一种呋虫胺的合成方法 | |
CN105330581A (zh) | 一种(s)-奥拉西坦的制备方法 | |
CN107513065B (zh) | 一种恩替卡韦中间体iv制备方法 | |
CN103087059B (zh) | 一种高纯度盐酸奥普力农的制备方法 | |
CN102786431A (zh) | 一种盐酸丙帕他莫的制备方法 | |
CN104592337B (zh) | 一种9-β-D-阿拉伯呋喃糖基-2-氟代腺嘌呤-5’-磷酸酯的制备方法 | |
CN102174007A (zh) | [2-(2-氰基-吡咯烷-1-基)-2-氧代-乙基]-氨基甲酸叔丁基酯的工业化制备方法 | |
CN105348164B (zh) | 一种1α‑羟基维生素D2的制备方法 | |
CN112321543A (zh) | 一种α-氯代-α乙酰基-γ-丁内酯的制备方法 | |
CN104628518A (zh) | 一种合成瑞格列奈关键中间体的方法 | |
CN103265443A (zh) | 一种工业生产高纯度亚氨基二乙酸的方法 | |
CN102718654A (zh) | 一种a-环戊基扁桃酸甲酯的制备方法 | |
CN103351339A (zh) | 3-氟代烷基-1-取代吡唑-4-羧酸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240202 Address after: 620000 first floor, office building 1, Jintai Road, Jinxiang Chemical Industrial Park, Meishan City, Sichuan Province Patentee after: Sichuan Nuobiao Biotechnology Co.,Ltd. Country or region after: China Address before: 610000 Building 1, No. 1480, north section of Tianfu Avenue, hi tech Zone, Chengdu, Sichuan Province Patentee before: CHENGDU NOVEL BIOCHEMICAL TECHNOLOGY CO.,LTD. Country or region before: China |
|
TR01 | Transfer of patent right |